Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB)

Price 1,210.00p on 18-12-2024 at 17:30:01
Change 0.00p 0%
Buy 1,250.00p
Sell 1,170.00p
Buy / Sell 4BB Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 1,400.00 at 1,170.00p
Day's Volume: 1,401
Last Close: 1,210.00p
Open: 1,210.00p
ISIN: GB00BMCLYF79
Day's Range 1,210.00p - 1,210.00p
52wk Range: 630.00p - 1,820.00p
Market Capitalisation: £187m
VWAP: 1,170.00057p
Shares in Issue: 15m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Recent Trades History 4basebio Plc (4BB)
Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 1,400 1,170.00p Negotiated Trade
 15:01:48 - 18-Dec-24
Sell* 1 1,170.80p Ordinary
 10:05:06 - 18-Dec-24

Share Price History for 4basebio Plc
Time period:
to
Date Open High Low Close Volume

Share News for 4basebio Plc

IN BRIEF: 4basebio to supply synthetic DNA for mRNA vaccine program

10th Apr 2024 11:21

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Announces the supply of its HQ synthetic DNA to an unnamed "Tier 1 pharma company". Says the client will use the synthetic DNA in late preclinical studies for an mRNA vaccine program. Financial details of the contract were not provided by 4basebio. Read More

4basebio updates markets on "key milestone" with client

21st Mar 2024 14:09

(Alliance News) - 4basebio PLC on Thursday noted a "key milestone" with its client, which is progressing into a phase one clinical trial. Read More

TRADING UPDATES: Alpha Real Trust says in "robust" financial shape

1st Mar 2024 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

IN BRIEF: 4basebio wins DNA supply contract to support RNA therapies

1st Mar 2024 14:04

4basebio PLC - Cambridge, England-based life-science tech company with proprietary technologies in the field of DNA synthesis - Announces success in tender process to supply research and GMP-grade synthetic DNA for the development of RNA therapeutics and vaccines at the CPI's RNA Centre of Excellence. The CPI is a UK government-supported organisation which offers development and scale-up services to companies. The Centre for Excellence is the name for its Darlington manufacturing facility. Read More

IN BRIEF: 4basebio interim loss widens as research costs increase

21st Sep 2023 21:14

4basebio PLC - Heidelberg, Germany-based life sciences company - Pretax loss in the six months to June 30 widens to GBP3.9 million from GBP2.7 million a year prior. Revenue grows 57% to GBP238,000 from GBP152,000. Research and non-captialised development expenses however increase 56% to GBP1.6 million from GBP1.0 million. Administrative expenses increase 23% to GBP1.6 million from GBP1.3 million, as sales and marketing expenses increase to GBP248,000 from GBP97,000. Looking ahead, expects to secure new clients in the second half of 2023. Read More

FTSE 100 Latest
Value8,199.11
Change3.91

Login to your account

Forgot Password?

Not Registered